Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLO-BEST: Allo-HSCT vs Standard of Care in Elderly AML
NCT04822766Phase 3Active, not recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Dec 2021
- Primary completion
- Jun 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia (AML), sponsored by Assistance publique - Hôpitaux de Paris. Started Dec 2021; status: active, not recruiting.
02
Drugs
allogeneic hematopoietic stem cell transplantation
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04822766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04822766.